PortalPublikationen[Clinical standing of valproate treatment of bipolar disorde...

[Clinical standing of valproate treatment of bipolar disorders]

Standard

[Clinical standing of valproate treatment of bipolar disorders]. / Grunze, H; Adli, M; Bauer, M; Berger, M; Bergmann, A; Bräunig, P; Bschor, T; Falkai, P; Gastpar, M; Greil, W; Kasper, S; Krüger, S; Laux, G; Müller, W E; Naber, Dieter; Walden, J.

in: FORTSCHR NEUROL PSYC, Jahrgang 75, Nr. 4, 4, 2007, S. 220-235.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Grunze, H, Adli, M, Bauer, M, Berger, M, Bergmann, A, Bräunig, P, Bschor, T, Falkai, P, Gastpar, M, Greil, W, Kasper, S, Krüger, S, Laux, G, Müller, WE, Naber, D & Walden, J 2007, '[Clinical standing of valproate treatment of bipolar disorders]', FORTSCHR NEUROL PSYC, Jg. 75, Nr. 4, 4, S. 220-235. <http://www.ncbi.nlm.nih.gov/pubmed/17427043?dopt=Citation>

APA

Grunze, H., Adli, M., Bauer, M., Berger, M., Bergmann, A., Bräunig, P., Bschor, T., Falkai, P., Gastpar, M., Greil, W., Kasper, S., Krüger, S., Laux, G., Müller, W. E., Naber, D., & Walden, J. (2007). [Clinical standing of valproate treatment of bipolar disorders]. FORTSCHR NEUROL PSYC, 75(4), 220-235. [4]. http://www.ncbi.nlm.nih.gov/pubmed/17427043?dopt=Citation

Vancouver

Grunze H, Adli M, Bauer M, Berger M, Bergmann A, Bräunig P et al. [Clinical standing of valproate treatment of bipolar disorders]. FORTSCHR NEUROL PSYC. 2007;75(4):220-235. 4.

Bibtex

@article{6eb1cd97abb14542b16aee1ae01cf6df,
title = "[Clinical standing of valproate treatment of bipolar disorders]",
abstract = "During recent years valproate has been established as a cornerstone for the drug-treatment of bipolar disorder. In Germany, valproate was licensed both for the treatment of acute mania and for maintenance treatment in summer 2005. At this occasion, this review summarises the scientific evidence and clinical experience of well-known experts with valproate-treatment. It was concluded that valproate will continue to be of high clinical significance despite the recent increase of treatment alternatives, both in monotherapy and combination treatment of acute mania, mixed states and maintenance treatment.",
author = "H Grunze and M Adli and M Bauer and M Berger and A Bergmann and P Br{\"a}unig and T Bschor and P Falkai and M Gastpar and W Greil and S Kasper and S Kr{\"u}ger and G Laux and M{\"u}ller, {W E} and Dieter Naber and J Walden",
year = "2007",
language = "Deutsch",
volume = "75",
pages = "220--235",
journal = "FORTSCHR NEUROL PSYC",
issn = "0720-4299",
publisher = "Georg Thieme Verlag KG",
number = "4",

}

RIS

TY - JOUR

T1 - [Clinical standing of valproate treatment of bipolar disorders]

AU - Grunze, H

AU - Adli, M

AU - Bauer, M

AU - Berger, M

AU - Bergmann, A

AU - Bräunig, P

AU - Bschor, T

AU - Falkai, P

AU - Gastpar, M

AU - Greil, W

AU - Kasper, S

AU - Krüger, S

AU - Laux, G

AU - Müller, W E

AU - Naber, Dieter

AU - Walden, J

PY - 2007

Y1 - 2007

N2 - During recent years valproate has been established as a cornerstone for the drug-treatment of bipolar disorder. In Germany, valproate was licensed both for the treatment of acute mania and for maintenance treatment in summer 2005. At this occasion, this review summarises the scientific evidence and clinical experience of well-known experts with valproate-treatment. It was concluded that valproate will continue to be of high clinical significance despite the recent increase of treatment alternatives, both in monotherapy and combination treatment of acute mania, mixed states and maintenance treatment.

AB - During recent years valproate has been established as a cornerstone for the drug-treatment of bipolar disorder. In Germany, valproate was licensed both for the treatment of acute mania and for maintenance treatment in summer 2005. At this occasion, this review summarises the scientific evidence and clinical experience of well-known experts with valproate-treatment. It was concluded that valproate will continue to be of high clinical significance despite the recent increase of treatment alternatives, both in monotherapy and combination treatment of acute mania, mixed states and maintenance treatment.

M3 - SCORING: Zeitschriftenaufsatz

VL - 75

SP - 220

EP - 235

JO - FORTSCHR NEUROL PSYC

JF - FORTSCHR NEUROL PSYC

SN - 0720-4299

IS - 4

M1 - 4

ER -